There is a quiet truth in oncology that never makes the press releases. Most cancer care does not happen in glass towers tied to academic prestige. It happens in community clinics where complexity...
There is a quiet truth in oncology that never makes the press releases. Most cancer care does not happen in glass towers tied to academic prestige. It happens in community clinics where complexity shows up early, data shows up late, and decisions still have to be right the first time. VieCure was built for that reality, not the brochure version.
Founded in 2015, VieCure did not chase noise. Brian Leyland-Jones and Fred Ashbury built it because precision medicine exploded faster than the systems meant to support it. Hundreds of therapies, diagnostics, biomarkers, and clinical pathways landed on clinicians already stretched thin. Halo Intelligence became the response. Not a dashboard. Not another inbox. An OS for community oncology that lets human intelligence stay in charge while AI handles the weight.
That vision just earned serious backing. VieCure closed a $43M growth round announced Jan 12, 2026, led by Mitch Rales alongside Northpond Ventures, with Durable Capital Partners, Socium Ventures backed by Cox Enterprises, and Sator Grove Holdings participating. This followed a $25M Series A in 2021 and a $45M round in late 2024, bringing total funding to $113M. Capital like this does not chase theory. It chases traction.
The numbers speak without shouting. 100+ community cancer centers. Nearly 30,000 patients managed on the platform. Tumor sequencing rates climbing nearly 8x. Guideline compliant treatment usage doubling. This is what happens when AI stops posturing and starts working inside real workflows, in real exam rooms, with real consequences.
Michael G. Power stepped into the CEO role in Dec 2023 after years building the foundation, and the execution shows. Rob Gibson is scaling the technology with the calm of someone who has seen healthcare systems break and fixed them anyway. Adam Seltser is keeping the financial engine disciplined. Fred Ashbury continues codifying the evidence that keeps Halo credible when it matters most.
The board mirrors the ambition. Richard Daly brings decades of healthcare scale. Mitch Rales adds operational gravity through New Bearing. Howard Burris brings the clinician's truth from the front lines. Andrea Jackson represents Northpond Ventures with long-game conviction.
VieCure is not chasing the future of oncology. It is dealing with the present, where most patients actually are. Halo Intelligence does not replace clinicians. It clears the fog so better decisions surface faster, inside community settings that treat over 80% of U.S. cancer patients.